Good Morning, It’s Monday Jan 09, 2012, I’m Christina Collins with CRWENewswire Stocks In Action. On its 1Q2012 2012, Acuity Brands Inc - AYI - posted net sales of $474.3M, an approximately 12% increase year over year. According to a definitive agreement between the companies, Bristol-Myers Squibb will acquire Inhibitex Inc - INHX - for $26.00 per share in cash pursuant to a cash tender offer and second step merger. and lastly; Idenix Pharmaceuticals Inc - IDIX - provided interim data from a 12-week phase IIb clinical trial of IDX184, its lead product candidate for the treatment of hepatitis C virus infection. According to the company, IDX184 has demonstrated a high barrier to resistance in vitro and potent antiviral activity in both preclinical and clinical studies. For CRWE Newswire, Stocks In Action, I’m Christina Collins

****

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)